Document:

<PAGE>

                                                                    Exhibit 10.2

================================================================================

                               WARRANT AGREEMENT

                                by and between

                      ENDO PHARMACEUTICALS HOLDINGS INC.

                                      and

                   UNITED STATES TRUST COMPANY OF NEW YORK,

                                      as

                                 Warrant Agent

                                  -----------

                           Dated as of July 17, 2000

                                  -----------

================================================================================
<PAGE>

<TABLE>
<CAPTION>
                               TABLE OF CONTENTS

                                                                            Page
                                                                            ----
<S>                                                                         <C>
Section 1.   Appointment of Warrant Agent................................      1
Section 2.   Warrant Certificates........................................      2
Section 3.   Execution of Warrant Certificates...........................      2
Section 4.   Registration and Countersignature...........................      3
Section 5.   Transfer and Exchange of Warrants...........................      3
Section 6.   Registration of Transfers and Exchanges.....................      5
Section 7.   Terms of Warrants; Exercise of Warrants.....................      8
Section 8.   Payment of Taxes............................................     11
Section 9.   Mutilated or Missing Warrant Certificates...................     12
Section 10.  Reservation of Warrant Shares...............................     12
Section 11.  Obtaining Stock Exchange Listings...........................     13
Section 12.  Adjustment of Exercise Price and Number of Warrant Shares
             Issuable....................................................     13
Section 13.  Fractional Interests........................................     20
Section 14.  Notices to Warrant Holders; Reservation of Dividends........     20
Section 15.  Notices to the Company and Warrant Agent....................     23
Section 16.  Supplements and Amendments; Actions.........................     24
Section 17.  Concerning the Warrant Agent................................     24
Section 18.  Change of Warrant Agent.....................................     27
Section 19.  Successors..................................................     28
Section 20.  Termination.................................................     28
Section 21.  GOVERNING LAW...............................................     28
Section 22.  Benefits of This Agreement..................................     28
Section 23.  Counterparts................................................     28
Section 24.  Headings....................................................     29
</TABLE>

                                       i
<PAGE>

     WARRANT AGREEMENT (the "Agreement"), dated as of July 17, 2000, by and
                             ---------
between Endo Pharmaceuticals Holdings Inc., a Delaware corporation (together
with any successors and assigns, the "Company"), and United States Trust Company
                                      -------
of New York, as Warrant Agent (the "Warrant Agent").
                                    -------------

     WHEREAS, pursuant to that certain Agreement and Plan of Merger, dated as of
November 26, 1999 (as may be amended and restated from time to time, the "Merger
                                                                          ------
Agreement"), by and among the Company, Endo Inc., a Delaware corporation and
---------
wholly owned subsidiary of the Company ("Sub"), and Algos Pharmaceutical
                                         ---
Corporation, a Delaware corporation ("Algos"), the Company proposes to issue
                                      -----
warrants (each a "Warrant," and collectively, the "Warrants") for the purchase
                  -------                          --------
of an aggregate of up to 20,575,507 shares of common stock, par value $.01 per
share, of the Company (the "Common Stock," and the shares of Common Stock
                            ------------
issuable upon exercise of the Warrants being referred to herein as the "Warrant
                                                                        -------
Shares");
------

     WHEREAS, there shall be two classes of Warrants, Class A which shall be
transferable ("Class A Transferable Warrants") and Class B which shall not be
               -----------------------------
transferable ("Class B Non-Transferable Warrants") and each holder of shares of
               ---------------------------------
common stock of Algos at the time of the stockholder vote relating to the Merger
Agreement may elect to receive all or a portion of such holder's Warrants to be
Class A Transferable Warrants or all or a portion of such holder's Warrants to
be Class B Non-Transferable Warrants and in the event any such holder of shares
of common stock of Algos does not make such an election, then such holder shall
be issued Class A Transferable Warrants. Such election, once made, will be
irrevocable;

     WHEREAS, the Company desires the Warrant Agent to act on behalf of the
Company and the Warrant Agent is willing to act in connection with the issuance,
transfer, exchange and exercise of Warrants as provided herein; and

     NOW, THEREFORE, in consideration of the premises and mutual agreements
herein, the Company and the Warrant Agent hereby agree as follows:

     Section 1.  Appointment of Warrant Agent. The Company hereby appoints
                 ----------------------------
the Warrant Agent to act as agent for the Company in accordance with the
instructions hereinafter set forth in this Agreement, and the Warrant Agent
hereby accepts such appointment.
<PAGE>

     Section 2.  Warrant Certificates. The Class A Transferable Warrants will
                 --------------------
initially be issued in global form (the "Global Warrants"), substantially in the
                                         ---------------
form of Exhibit A hereto. Any certificates evidencing the Global Warrants to be
delivered pursuant to this Agreement (the "Class A Warrant Certificates") shall
                                           ----------------------------
be substantially in the form set forth in Exhibit A hereto. Such Global Warrants
shall represent such of the outstanding Class A Transferable Warrants as shall
be specified therein and each shall provide that it shall represent the
aggregate amount of outstanding Class A Transferable Warrants from time to time
endorsed thereon and that the aggregate amount of outstanding Class A
Transferable Warrants represented thereby may from time to time be reduced or
increased, as appropriate. Any endorsement of a Global Warrant to reflect the
amount of any increase or decrease in the amount of outstanding Class A
Transferable Warrants represented thereby shall be made by the Warrant Agent and
the Depositary (as defined below) in accordance with instructions given by the
holder thereof. The Depository Trust Company shall act as the Depositary with
respect to the Global Warrants until a successor shall be appointed by the
Company. Upon written request, a Warrant holder who holds Class A Transferable
Warrants may receive from the Depositary and Warrant Agent Class A Transferable
Warrants in registered form as definitive Warrant Certificates (the "Definitive
                                                                     ----------
Warrants") as set forth in Section 6 below. Class B Non-Transferable Warrants
--------
will be issued in certificated form, in the name of and in the denomination as
set forth in the applicable letter of transmittal accompanying the shares of
common stock of Algos surrendered by the holder thereof in connection with the
merger of Algos with and into Sub pursuant to the Merger Agreement.

     Section 3.  Execution of Warrant Certificates. Warrant Certificates shall
                 ---------------------------------
be signed on behalf of the Company by its Chairman of the Board, its President,
Chief Executive Officer, Chief Operating Officer, Chief Financial Officer or
Treasurer or a Vice President and by its Secretary or an Assistant Secretary.

     Each such signature upon the Warrant Certificates may be in the form of
a facsimile signature of the present or any future Chairman of the Board,
President, Chief Executive Officer, Chief Operating Officer, Chief Financial
Officer, Treasurer, Vice President, Secretary or Assistant Secretary and may be
imprinted or otherwise reproduced on the Warrant Certificates and for that
purpose the Company may adopt and use the facsimile signature of any person who
shall have been Chairman of the Board, President, Chief Executive Officer, Chief
Operating Officer, Chief Financial Officer, Treasurer, a Vice President,
Secretary or an Assistant Secretary, notwithstanding the fact that at the time
the Warrant Certificates shall be countersigned and delivered or disposed of
such person shall have ceased to hold such office.

                                       2
<PAGE>

     In case any officer of the Company who shall have signed any of the Warrant
Certificates shall cease to be such officer before the Warrant Certificates so
signed shall have been countersigned by the Warrant Agent, or disposed of by the
Company, such Warrant Certificates nevertheless may be countersigned and
delivered or disposed of as though such person had not ceased to be such officer
of the Company; and any Warrant Certificate may be signed on behalf of the
Company by any person who, at the actual date of the execution of such Warrant
Certificate, shall be a proper officer of the Company to sign such Warrant
Certificate, although at the date of the execution of this Warrant Agreement any
such person was not such officer.

     Warrant Certificates shall be dated the date of countersignature by the
Warrant Agent.

     Section 4.  Registration and Countersignature. The Warrants shall be
                 ---------------------------------
numbered and shall be registered on the books of the Company maintained at the
principal office of the Warrant Agent in located at 114 West 47th Street, 25th
Floor, New York, New York, 10036, Attention: Corporate Trust Division (the
"Warrant Register") as they are issued.
 ----------------

     Warrant Certificates shall be manually countersigned by the Warrant Agent
and shall not be valid for any purpose unless so countersigned. The Warrant
Agent shall, upon written instructions of the Chairman of the Board, the
President, Chief Executive Officer, Chief Operating Officer, Chief Financial
Officer, Treasurer, a Vice President, the Secretary or an Assistant Secretary of
the Company, initially countersign and deliver Warrants entitling the holders
thereof to purchase not more than the number of Warrant Shares referred to above
in the first recital hereof and shall thereafter countersign and deliver
Warrants as otherwise provided in this Agreement.

     The Company and the Warrant Agent may deem and treat the registered holders
(the "Holders") of the Warrant Certificates as the absolute owners thereof
      -------
(notwithstanding any notation of ownership or other writing thereon made by
anyone) for all purposes, and neither the Company nor the Warrant Agent shall be
affected by any notice to the contrary.

     Section 5.  Transfer and Exchange of Warrants. The Warrant Agent shall from
                 ---------------------------------
time to time, subject to the limitations of Section 6 hereof, register the
transfer of any outstanding Warrants upon the records to be maintained by it for
that purpose, upon surrender thereof duly endorsed or accompanied (if so
required by it) by a written instrument or instruments of transfer in form
satisfactory to the Warrant

                                       3
<PAGE>

Agent and a certificate in the form of Exhibit B hereto, in each case, duly
executed by the registered Holder or Holders thereof or by the duly appointed
legal representative thereof or by a duly authorized attorney; provided that
                                                               -------- ----
Class B Non-Transferable Warrants may only be transferred (i) as the result or
assignment by operation of law (such as death or merger or otherwise) or (ii) as
required by law or any court of competent jurisdiction (such as in connection
with divorce, bankruptcy or liquidation). A request for a transfer of a Class B
Non-Transferable Warrant shall be accompanied by such documentation establishing
satisfaction of the conditions set forth in clause (i) or (ii) above, as
applicable, as may be reasonably requested by the Company (including opinions of
counsel, if appropriate). Upon receipt of documentation reasonably satisfactory
to the Company, the Company shall authorize the Warrant Agent to permit the
transfer of a Class B Non-Transferable Warrant. The Warrant Agent shall not
permit the transfer of a Class B Non-Transferable Warrant until it is so
authorized by the Company. Unless otherwise authorized by the Company, Class B
Non-Transferable Warrant Certificate may only be transferred for another Class B
Non-Transferable Warrant Certificate. Subject to the terms of this Agreement,
each Warrant Certificate may be exchanged for another certificate or
certificates entitling the Holder thereof to purchase a like aggregate number of
Warrant Shares as the certificate or certificates surrendered then entitle each
Holder to purchase. Any Holder desiring to exchange a Warrant Certificate or
Certificates shall make such request in writing delivered to the Warrant Agent,
and shall surrender, duly endorsed or accompanied (if so required by the Warrant
Agent) by a written instrument or instruments of transfer in form satisfactory
to the Warrant Agent, the Warrant Certificate or Certificates to be so
exchanged.

     Upon registration of transfer, the Warrant Agent shall countersign and
deliver by certified or first class mail a new Warrant Certificate or
Certificates to the persons entitled thereto. The Warrant Certificates may be
exchanged at the option of the Holder thereof, when surrendered at the office or
agency of the Company maintained for such purpose, which initially will be the
corporate trust office of the Warrant Agent located at 30 Broad Street, 14th
Floor, New York, New York, 10004-2304, Attention: Corporate Trust Services, for
another Warrant Certificate, or other Warrant Certificates of different
denominations, of like tenor and representing in the aggregate the right to
purchase a like number of Warrant Shares.

     No service charge shall be made for any exchange or registration of
transfer of Warrant Certificates, but the Company may require payment of a sum
sufficient to cover any stamp or other tax or other governmental charge that is
imposed in connection with any such exchange or registration of transfer.

                                       4
<PAGE>

     Section 6.  Registration of Transfers and Exchanges.
                 ---------------------------------------

     (a)  Transfer and Exchange of Definitive Warrants. When Definitive Warrants
are presented to the Warrant Agent with a request:

          (i)  to register the transfer of the Definitive Warrants; or

          (ii) to exchange such Definitive Warrants for an equal number of
     Definitive Warrants of other authorized denominations, the Warrant Agent
     shall register the transfer or make the exchange as requested if its
     requirements under this Agreement are met; provided, however, that the
     Definitive Warrants presented or surrendered for registration of transfer
     or exchange shall be duly endorsed or accompanied by a written instruction
     of transfer in form satisfactory to the Warrant Agent, duly executed by the
     Holder thereof or by such Holder's attorney, duly authorized in writing;
     provided that a transfer of Definitive Warrants that are Class B Non-
     Transferable Warrants shall be subject to the requirements of Section 5
     hereof.

          (b)  Restrictions on Transfer of a Definitive Warrant for a Beneficial
Interest in a Global Warrant. The Warrant Agent may exchange a Definitive
Warrant for a beneficial interest in a Global Warrant only if the Warrant Agent
has received such Definitive Warrant, duly endorsed or accompanied by
appropriate instruments of transfer, in form satisfactory to the Warrant Agent,
together with written instructions directing the Warrant Agent to make, or to
direct the Depositary to make, an endorsement on the Global Warrant to reflect
an increase in the aggregate amount of the Warrants represented by the Global
Warrant. If such conditions have been satisfied, the Warrant Agent shall cancel
such Definitive Warrant and cause, or direct the Depositary to cause, in
accordance with the standing instructions and procedures existing between the
Depositary and the Warrant Agent, the number of Warrant Shares represented by
the Global Warrant to be increased accordingly. If no Global Warrant is then
outstanding, the Company shall issue and the Warrant Agent shall countersign a
new Global Warrant in the appropriate amount.

          (c)  Transfer and Exchange of Global Warrants. The transfer and
exchange of Global Warrants or beneficial interests therein shall be effected
through the Depositary, in accordance with this Warrant Agreement (including the
restrictions on transfer set forth herein) and the procedures of the Depositary
therefor.

          (d)  Transfer of a Beneficial Interest in a Global Warrant for a
Definitive Warrant.

                                       5
<PAGE>

          (i)  Any person having a beneficial interest in a Global Warrant may
     upon his, her or its request exchange such beneficial interest for a
     Definitive Warrant. Upon receipt by the Warrant Agent of written
     instructions (or such other form of instructions as is customary for the
     Depositary) from the Depositary or its nominee on behalf of any person
     having a beneficial interest in a Global Warrant and upon receipt by the
     Warrant Agent of a written order or such other form of instructions as is
     customary for the Depositary or the person designated by the Depositary as
     having such a beneficial interest containing registration instructions,
     then the Warrant Agent will cause, in accordance with the standing
     instructions and procedures existing between the Depositary and the Warrant
     Agent, the aggregate amount of the Global Warrant to be reduced and,
     following such reduction, the Company will execute and, upon receipt of a
     countersignature, the Warrant Agent will countersign and deliver to the
     transferee a Definitive Warrant. All such Warrants shall be Class A
     Transferable Warrants.

          (ii) Definitive Warrants issued in exchange for a beneficial interest
     in a Global Warrant pursuant to this Section 6(d) shall be registered in
     such names and in such authorized denominations as the Depositary, pursuant
     to instructions from its direct or indirect participants or otherwise,
     shall instruct the Warrant Agent in writing, provided such designation is
     in accordance with this Section 6(d). The Warrant Agent shall deliver such
     Definitive Warrants to the persons in whose names such Definitive Warrants
     are registered.

     (e)  Restrictions on Transfer and Exchange of Global Warrants.
Notwithstanding any other provisions of this Warrant Agreement (other than the
provisions set forth in subsection (f) of this Section 6), a Global Warrant may
not be transferred as a whole except by the Depositary to a nominee of the
Depositary or by a nominee of the Depositary to the Depositary or another
nominee of the Depositary or by the Depositary or any such nominee to a
successor Depositary or a nominee of such successor Depositary.

     (f)  Authentication of Definitive Warrants in Absence of Depositary. If at
any time:

          (i)  the Depositary for the Global Warrants notifies the Company that
     the Depositary is unwilling or unable to continue as Depositary for the

                                       6
<PAGE>

     Global Warrant and a successor Depositary for the Global Warrant is not
     appointed by the Company within 90 days after delivery of such notice; or

          (ii) the Company, at its sole discretion, notifies the Warrant Agent
     in writing that it elects to cause the issuance of Definitive Warrants
     under this Warrant Agreement, then the Company will execute, and the
     Warrant Agent, upon receipt of an officers' certificate, signed by the
     President, Chief Executive Officer, Chief Operating Officer, Chief
     Financial Officer or a Vice President of the Company, requesting the
     countersignature and delivery of Definitive Warrants, will countersign and
     deliver Definitive Warrants, in an aggregate number equal to the aggregate
     number of Warrants represented by the Global Warrant, in exchange for such
     Global Warrant.

     (g)  Cancellation and/or Adjustment of a Global Warrant. At such time as
all beneficial interests in a Global Warrant have either been exchanged for
Definitive Warrants, redeemed, repurchased or cancelled, such Global Warrant
shall be returned to or retained and cancelled by the Warrant Agent. At any time
prior to such cancellation, if any beneficial interest in a Global Warrant is
exchanged for Definitive Warrants, redeemed, repurchased or cancelled, the
number of Warrants represented by such Global Warrant shall be reduced and an
endorsement shall be made on such Global Warrant, by the Warrant Agent to
reflect such reduction.

     (h)  Obligations with Respect to Transfers and Exchanges of Definitive
Warrants.

          (i)   To permit registrations of transfers and exchanges in accordance
     with the terms of this Agreement, the Company shall execute, and the
     Warrant Agent shall countersign Definitive Warrants and Global Warrants.

          (ii)  All Definitive Warrants and Global Warrants issued upon any
     registration, transfer or exchange of Definitive Warrants or Global
     Warrants shall be the valid obligations of the Company, entitled to the
     same benefits under this Warrant Agreement as the Definitive Warrants or
     Global Warrants surrendered upon the registration of transfer or exchange.

          (iii) Prior to due presentment for registration of transfer of any
     Warrant, the Warrant Agent and the Company may deem and treat the person in
     whose name any Warrant is registered as the absolute owner of such Warrant,
     and neither the Warrant Agent nor the Company shall be affected by notice
     to the contrary.

                                       7
<PAGE>

     Section 7.  Terms of Warrants; Exercise of Warrants. Subject to the terms
                 ---------------------------------------
of this Agreement, each Warrant Holder shall have the right, which may be
exercised commencing on or after the Exercisability Date (as defined below) and
until 5:00 p.m., New York City time, on the six-month anniversary of the
Exercisability Date (the "Expiration Date"), to receive from the Company the
                          ---------------
number of fully paid and nonassessable Warrant Shares which the Holder may at
the time be entitled to receive on exercise of such Warrants and payment of the
Exercise Price (as defined below) then in effect for such Warrant Shares
together, if applicable, with cash payable as provided in Section 13 hereof and
any dividends or distributions payable as provided in Section 14 hereof. If the
Exercisability Date is on or prior to March 31, 2002, the Holders shall then be
entitled to receive from the Company (on exercise of such Warrants and payment
of the Exercise Price then in effect for such Warrant Shares) (together, if
applicable, with cash payable as provided in Section 13 hereof and any dividends
or distributions payable as provided in Section 14 hereof) (a) 20,575,507
Warrant Shares (in the aggregate) (with each Warrant being exercisable for
1.153846 Warrant Shares) in the event the Adjustment Event (as defined in the
Merger Agreement) has not occurred prior to the Exercisability Date or (b)
17,832,106 Warrant Shares (in the aggregate) (with each Warrant being
exercisable for 1.000000 Warrant Shares) in the event the Adjustment Event has
occurred prior to the Exercisability Date. If the Exercisability Date is after
March 31, 2002 and on or prior to September 30, 2002, the Holder shall then be
entitled to receive from the Company (on exercise of such Warrants and payment
of the Exercise Price then in effect for such Warrant Shares) (together, if
applicable, with cash payable as provided in Section 13 hereof and any dividends
or distributions payable as provided in Section 14 hereof) (a) 11,302,039
Warrant Shares (in the aggregate) (with each Warrant being exercisable for
0.633803 Warrant Shares) in the event the Adjustment Event has not occurred
prior to the Exercisability Date or (b) 9,726,603 Warrant Shares (in the
aggregate) (with each Warrant being exercisable for 0.545455 Warrant Shares) in
the event the Adjustment Event has occurred prior to the Exercisability Date. If
the Exercisability Date is after September 30, 2002 and on or prior to March 31,
2003 (the "Ultimate Expiration Date"), the Holders shall then be entitled to
           ------------------------
receive from the Company (on exercise of such Warrants and payment of the
Exercise Price then in effect for such Warrant Shares) (together, if applicable,
with cash payable as provided in Section 13 hereof and any dividends or
distributions payable as provided in Section 14 hereof) (a) 4,692,659 Warrant
Shares (in the aggregate) (with each Warrant being exercisable for 0.263158
Warrant Shares) the event the Adjustment Event has not occurred prior to the
Exercisability Date or (b) 4,018,503 Warrant Shares (in the aggregate) (with
each Warrant being exercisable for 0.225352 Warrant Shares) in the event the
Adjustment Event has

                                       8
<PAGE>

occurred prior to the Exercisability Date. Each Warrant not exercised prior to
the Expiration Date shall become void and all rights thereunder and all rights
in respect thereof under this Agreement shall cease as of the Expiration Date.
Without limiting the foregoing, in the event the Ultimate Expiration Date occurs
before the Exercisability Date, each Warrant shall become void and all rights
thereunder and all rights in respect thereof under this Agreement shall cease as
of the Ultimate Expiration Date. If applicable, dividends and other
distributions will be made upon exercise of the Warrants as set forth in Section
14 hereof. "Exercisability Date" shall mean the fifth (5th) Business Day (as
            -------------------
defined below) following the date on which the Company (or any of its
subsidiaries) receives approval from the U.S. Food and Drug Administration (the
"FDA") with respect to its New Drug Application for MorphiDex(R) for the
 ---
treatment of one or more pain indications. In addition to the notices required
by Section 14 hereof, the Company shall give prompt written notice to the
Warrant Agent that the Exercisability Date has occurred and shall cause the
Warrant Agent, on behalf of and at the expense of the Company, within 5 Business
Days after such notification is received by the Warrant Agent, to mail by first
class mail, postage prepaid, to each Holder a notice specifying that the
Exercisability Date has occurred and that the Warrant has become exercisable
pursuant to its terms and that the Warrant will expire at 5:00 p.m., New York
City time, on the Expiration Date. In addition, the Company shall post
appropriate notices of the Exercisability Date on its web pages and issue press
releases to wire services. A "Business Day" is a day that is not a Legal
                              ------------
Holiday. A "Legal Holiday" is a Saturday, a Sunday, a federally recognized
            -------------
holiday or a day on which banking institutions are not required to be open in
the State of New York. From and after the Effective Time, Parent agrees to use
its reasonable efforts to continue to process the FDA application for
MorphiDex(R) in a timely fashion. The parties acknowledge that there are many
variables in the process of obtaining FDA approval in such a situation and many
different approaches which may be used by an applicant in order to obtain such
approval; as a result, the parties hereto agree that all determinations relating
to such process and all actions taken in connection with seeking such approval
shall be in the sole discretion of Parent and shall be binding upon the parties
for all purposes.

     The parties further acknowledge that (i) on August 2, 1999, the Company
received notification from the FDA that such application was not approvable,
(ii) the failure to obtain such approval, either at all or on or before a
certain date, shall not be deemed a breach by Parent of the provisions hereof
and (iii) in any event Parent shall have no responsibility in connection with
the provisions of this paragraph, except for its willful breach hereof.

                                       9
<PAGE>

     The initial price per share at which Warrant Shares shall be purchasable
upon exercise of Warrants (the "Exercise Price") shall equal $0.01. A Warrant
                                --------------
may be exercised upon surrender at the office or agency of the Company
maintained for such purpose, which initially will be the corporate trust office
of the Warrant Agent or its agents in located at 114 West 47th Street, 25th
Floor, New York, New York, 10036, Attention: Corporate Trust Division of the
Warrant Certificate(s) evidencing the Warrants to be exercised with the form of
election to purchase on the reverse thereof duly filled in and signed, which
signature shall be guaranteed by a participant in a recognized Signature
Guarantee Medallion Program, and upon payment to the Warrant Agent for the
account of the Company of the Exercise Price, as adjusted as herein provided,
for the number of Warrant Shares together, if applicable, with cash payable as
provided in Section 13 hereof and any dividends or distributions as provided in
Section 14 hereof in respect of which such Warrants are then exercised. Payment
of the Exercise Price may be made (a) in the form of cash or by certified or
official bank check payable to the order of the Company in New York Clearing
House Funds, (b) by delivering to the Company a written notice accompanying the
surrender of a Warrant to, at the time of exercise, apply to the payment of the
Exercise Price such number of Warrant Shares as shall be specified in such
notice, in which case an amount equal to the excess of the Current Market Value
(as defined in Section 12(d) hereof) of such Warrant Shares on the date of
exercise over the Exercise Price required for such exercise shall be deemed to
have been paid to the Company and the number of Warrant Shares issuable upon
such exercise shall be reduced by such specified number (a "Cashless Exercise")
                                                            -----------------
or (c) any combination of (a) and (b) above. Subject to the provisions of
Section 6 hereof, upon such surrender of Warrants and payment of the Exercise
Price, the Company shall issue and cause to be delivered with all reasonable
dispatch to or upon the written order of the Holder and in such name or names as
the Warrant Holder may designate a certificate or certificates for the number of
full Warrant Shares issuable upon the exercise of such Warrants together with
cash as provided in Section 13 hereof. Such certificate or certificates shall be
deemed to have been issued and any person so named therein shall be deemed to
have become a holder of record of such Warrant Shares as of the date of the
surrender of such Warrants and payment of the Exercise Price. On or after the
Exercisability Date, the Warrants shall be exercisable, at the election of the
Holders thereof, either in full or from time to time in part and, in the event
that a certificate evidencing Warrants is exercised in respect of fewer than all
of the Warrant Shares issuable on such exercise at any time prior to the
Expiration Date, a new certificate evidencing the remaining Warrant or Warrants
will be issued, and the Warrant Agent is hereby irrevocably authorized to
countersign and to deliver the required new Warrant Certificate or Certificates
pursuant to the provisions of this Section 7 and of Section 3 hereof, and the
Company, whenever required by the

                                      10
<PAGE>

Warrant Agent, will promptly supply the Warrant Agent with Warrant Certificates
duly executed on behalf of the Company for such purpose.

     All Warrant Certificates surrendered upon exercise of Warrants shall be
cancelled by the Warrant Agent. Such cancelled Warrant Certificates shall then
be either delivered to the Company or disposed of by the Warrant Agent in a
manner consistent with the Warrant Agent's customary procedure for such disposal
and in a manner reasonably satisfactory to the Company. The Warrant Agent shall
account promptly to the Company with respect to Warrants exercised and
concurrently pay to the Company all monies received by the Warrant Agent for the
purchase of the Warrant Shares through the exercise of such Warrants.

     The Warrant Agent shall keep copies of this Agreement available for
inspection by the Holders during normal business hours at its office. The
Company shall supply the Warrant Agent from time to time with such numbers of
copies of this Agreement as the Warrant Agent may request.

     Section 8.  Payment of Taxes. The Company will pay all documentary stamp
                 ----------------
taxes attributable to the initial issuance of Warrant Shares upon the exercise
of Warrants; provided, however, that the Company shall not be required to pay
any tax or taxes which may be payable in respect of any transfer involved in the
issue of any Warrant Certificates or any certificates for Warrant Shares in a
name other than that of the registered Holder of a Warrant Certificate
surrendered upon the exercise of a Warrant, and the Company shall not be
required to issue or deliver such Warrant Certificates unless or until the
person or persons requesting the issuance thereof shall have paid to the Company
the amount of such tax or shall have established to the satisfaction of the
Company that such tax has been paid.

     Section 9.  Mutilated or Missing Warrant Certificates. In case any of the
                 -----------------------------------------
Warrant Certificates shall be mutilated, lost, stolen or destroyed, the Company
may in its discretion issue and the Warrant Agent may countersign, in exchange
and substitution for and upon cancellation of the mutilated Warrant Certificate,
or in lieu of and substitution for the Warrant Certificate lost, stolen or
destroyed, a new Warrant Certificate of like tenor and representing an
equivalent number of Warrants, but only upon receipt of evidence satisfactory to
the Company and the Warrant Agent of such loss, theft or destruction of such
Warrant Certificate and indemnity, if requested, also satisfactory to them.
Applicants for such substitute Warrant Certificates shall also comply with such
other reasonable regulations and pay such other reasonable charges as the
Company or the Warrant Agent may prescribe.

                                      11
<PAGE>

     Section 10.  Reservation of Warrant Shares. The Company will at all times
                  -----------------------------
reserve and keep available, free from preemptive rights, out of the aggregate of
its authorized but unissued Common Stock or its authorized and issued Common
Stock held in its treasury, for the purpose of enabling it to satisfy any
obligation to issue Warrant Shares upon exercise of Warrants, the maximum number
of shares of Common Stock which may then be deliverable upon the exercise of all
outstanding Warrants.

     The Company will keep a copy of this Agreement on file with the transfer
agent for the Common Stock (the "Transfer Agent") and with every subsequent
                                 --------------
transfer agent for any shares of the Company's capital stock issuable upon the
exercise of the rights of purchase represented by the Warrants. The Warrant
Agent is hereby irrevocably authorized to requisition from time to time from
such Transfer Agent the stock certificates required to honor outstanding
warrants upon exercise thereof in accordance with the terms of this Agreement.
The Company will supply such Transfer Agent with duly executed certificates for
such purposes and will provide or otherwise make available any cash which may be
payable as provided in Section 13 hereof. The Company will furnish such Transfer
Agent a copy of all notices of adjustments and certificates related thereto
transmitted to each Holder pursuant to Section 14 hereof.

     The Company covenants that all Warrant Shares which may be issued upon
exercise of Warrants will, upon payment of the Exercise Price therefor and
issue, be validly authorized and issued, fully paid, nonassessable, free of
preemptive rights and free from all taxes, liens, charges and security interests
with respect to the issuance thereof. The Company will use its reasonable best
efforts to obtain all such authorizations, exemptions or consents from any
public regulatory body having jurisdiction thereof as may be necessary to enable
the Company to perform its obligations under this Agreement.

     Section 11. Obtaining Stock Exchange Listings. The Company will from time
                 ---------------------------------
to time take all action which may be necessary so that the Warrants and,
immediately upon their issuance upon exercise of the Warrants, the Warrant
Shares will be listed on the principal securities exchanges and markets within
the United States of America, if any, on which other shares of Common Stock are
then listed.

                                      12
<PAGE>

     Section 12.  Adjustment of Exercise Price and Number of Warrant Shares
                  ---------------------------------------------------------
Issuable.
--------

     (a)  If the Company:

          (i)  pays a dividend or makes a distribution on its Common Stock in
     shares of its Common Stock or other capital stock of the Company; or

          (ii) subdivides, splits, combines or reclassifies its outstanding
     shares of Common Stock into a different number of securities of the same
     class, then the number of shares of Common Stock issuable upon the exercise
     of each Warrant (the "Exercise Rate") in effect immediately prior to such
                           -------------
     action shall be proportionately adjusted so that the Holder of any Warrant
     thereafter exercised may receive the aggregate number and kind of shares of
     capital stock of the Company which such Holder would have owned immediately
     following such action if such Warrant had been exercised immediately prior
     to such action and the Exercise Price in effect immediately prior to such
     action shall be adjusted to a price determined by multiplying the Exercise
     Price in effect immediately prior to such action by a fraction, the
     numerator of which shall be the number of shares of Common Stock
     outstanding before giving effect to such action and the denominator of
     which shall be the number of shares of Common Stock and/or such other
     capital stock outstanding referred to in the foregoing clause (a)(1) after
     giving effect to such action.

     An adjustment pursuant to this Section 12(a) shall become effective
immediately after the record date in the case of a dividend or distribution and
immediately after the effective date in the case of a subdivision, combination
or reclassification. If, after an adjustment pursuant to this Section 12(a), a
Holder of a Warrant upon exercise of it may receive shares of two or more
classes of capital stock of the Company, the board of directors of the Company
shall determine the allocation of the adjusted Exercise Price between the
classes of capital stock. After such allocation, the exercise privilege and the
Exercise Price of each class of capital stock shall thereafter be subject to
adjustment on terms comparable to those applicable to Common Stock in this
Section 12.

     Such adjustment shall be made successively whenever any event listed above
shall occur.

                                      13
<PAGE>

     (b)  Adjustment for Certain Issuances of Common Stock. If the Company
issues or sells to any Affiliate (as defined in Section 12(d) hereof) of the
Company shares of its Common Stock or distributes to any Affiliate of the
Company any rights, options or warrants entitling them to purchase shares of
Common Stock, or securities convertible into or exchangeable for Common Stock,
in each case, at a price per share less than the Current Market Value on the
record date for determining entitlements of such Affiliates to participate in
such issuance, sale or distribution (the "Time of Determination") and prior to
                                          ---------------------
such issuance, sale or distribution the Company did not first offer to issue,
sell or distribute such shares of its Common Stock or such rights, options or
warrants or such securities convertible into or exchangeable for Common Stock to
all holders of Common Stock on the same economic terms and on a pro rata basis
with the issuance, sale or distribution to the Affiliates of the Company, then
the Exercise Rate shall be adjusted in accordance with the formula:

                                E' = E x O + N
                                         -----
                                      O + N x P
                                          -----
                                             M

and the Exercise Price shall be adjusted in accordance with the following
formula:

                                EP' = EP x E
                                           -
                                           E'

where:

     E' =   the adjusted Exercise Rate.

     E  =   the Exercise Rate immediately prior to the Time of Determination for
            any such issuance, sale or distribution.

     EP' =  the Adjusted Exercise Price.

     EP  =  the Exercise Price immediately prior to the Time of Determination
            for any such issuance, sale or distribution.

                                      14
<PAGE>

         O =      the number of Fully Diluted Shares (as defined below)
                  outstanding immediately prior to the Time of Determination for
                  any such issuance, sale or distribution.

         N =      the number of additional shares of Common Stock issued, sold
                  or issuable upon exercise of such rights, options or warrants.

         P =      the per share price received and receivable by the Company
                  in the case of any issuance or sale of Common Stock or rights,
                  options or warrants as to which such adjustment is being made,
                  inclusive of the exercise price per share of Common Stock
                  payable upon exercise of such rights, options or warrants.

         M =      the Current Market Value per share of Common Stock on the
                  Time of Determination for any such issuance, sale or
                  distribution.

         For purposes of this Section 12(b), the term "Fully Diluted Shares"
                                                       --------------------
shall mean (i) the shares of Common Stock outstanding as of a specified date,
and (ii) the shares of Common Stock into or for which rights, options, warrants
or other securities of the Company outstanding as of such date are exercisable
or convertible (other than the Warrants).

         Any adjustments shall be made successively whenever any such rights,
options or warrants are issued and shall become effective immediately after the
relevant Time of Determination. Notwithstanding the foregoing, the Exercise Rate
and the Exercise Price shall not be subject to adjustment in connection with (i)
the issuance of any shares of Common Stock upon exercise of any such rights,
options or warrants which have previously been the subject of an adjustment
under this Agreement for which the required adjustment has been made and (ii)
any exercise of the Warrants. If at the end of the period during which any such
rights, options or warrants are exercisable, not all rights, options or warrants
shall have been exercised, the Warrant shall be immediately readjusted to what
it would have been if "N" in each of the above formulas had been the number of
shares actually issued.

         (c)  When De Minimis Adjustment May Be Deferred. No adjustment in the
Exercise Rate need be made unless the adjustment would require an increase or
decrease of at least 1% in the Exercise Rate. Notwithstanding the foregoing, any
adjustments that are not made shall be carried forward and taken into account in
any subsequent adjustment, provided that no such adjustment shall be deferred
beyond the date on which a Warrant is exercised.

                                      15
<PAGE>

         All calculations under this Section 12 shall be made to the nearest
cent or to the nearest 1/100th of a share, as the case may be.

         (d)  Certain Definitions. "Current Market Value" per share of Common
                                    --------------------
Stock or of any other security (herein collectively referred to as a "Security")
                                                                      --------
at any date shall be:

              (1) if the Security is not registered under the Securities
         Exchange Act of 1934, as amended (the "Exchange Act"), (i) the value of
                                                ------------
         the Security determined in good faith by the board of directors of the
         Company and certified in a board resolution, based on the most recently
         completed arm's-length transaction between the Company and a person
         other than an Affiliate of the Company and the closing of which occurs
         on such date or shall have occurred within the six months preceding
         such date or (ii) if no such transaction shall have occurred on such
         date or within such six-month period, the value of the Security
         determined as of a date within 30 days preceding such date by an
         Independent Financial Expert (as defined below), or

              (2) if the Security is registered under the Exchange Act, the
         average of the daily closing bid prices of such Security for 30
         consecutive Business Days selected by the Company from the period of 45
         Business Days preceding such date, but only if such Security shall have
         been listed on a national securities exchange or the Nasdaq National
         Market or traded through an automated quotation system during such
         entire 45-Business Day period.

         The "closing bid price" for any Security on each Business Day means the
              -----------------
closing price, regular way, on such day on the principal exchange on which such
Security is traded, or if no sale takes place on such day, the average of the
closing bid and asked prices on such day.

         "Independent Financial Expert" shall mean any nationally recognized
          ----------------------------
investment banking firm that is not an Affiliate of the Company. Any such person
may receive customary compensation and indemnification by the Company for
opinions or services it provides as an Independent Financial Expert.

         "Affiliate" of any specified person means any other person which
          ---------
directly or indirectly through one or more intermediaries controls or is
controlled by, or is under common control with, such specified person. For the
purposes of this definition, "control" (including with correlative meanings, the
terms "controlling," "controlled

                                      16
<PAGE>

by" and "under common control with") as used with respect to any person, means
the possession, directly or indirectly, of the power to direct or cause the
direction of the management and policies of such person, whether through the
ownership of voting securities, by agreement or otherwise.

         "Ordinary Cash Distribution" means any quarterly cash dividend on the
          --------------------------
Common Stock to the extent that the aggregate cash dividend per share of Common
Stock in any calendar quarter does not exceed the greater of (x) the amount per
share of Common Stock of the next preceding quarterly cash dividend on the
Common Stock (as adjusted to reflect subdivisions or combinations of the Common
Stock) and (y) 3.0% of the average of the last reported sales prices of the
Common Stock during the ten trading days immediately prior to the date of
declaration of such dividend.

         (e)  When No Adjustment Required. If an adjustment is made upon the
establishment of a record date for an issuance, sale or distribution subject to
subsection (a) or (b) hereof and such issuance, sale or distribution is
subsequently cancelled or is not otherwise made, the Exercise Rate and Exercise
Price then in effect shall be readjusted, effective as of the date when the
board of directors of the Company determines to cancel such issuance, sale or
distribution or when it is otherwise evident that such issuance, sale or
distribution will not be so made, to that which would have been in effect if
such record date had not been fixed. If an adjustment would be required under
both subsections (a) and (b) above, such adjustments will be determined without
duplication.

         To the extent the Warrants become convertible into cash, no adjustment
need be made thereafter as to the amount of cash into which such Warrants are
exercisable. Interest will not accrue on the cash.

         (f)  Notice of Adjustment. Whenever the Exercise Rate or Exercise Price
is adjusted, the Company shall provide the notices required by Section 14
hereof.

         (g)  Voluntary Reduction. The Company from time to time may increase
the Exercise Rate or reduce the Exercise Price by any amount for any period of
time (including, without limitation, permanently) if the period is at least 20
Business Days after the Company has given notice of such increase or reduction
in accordance with Section 14 hereof.

         An increase of the Exercise Rate or reduction in the Exercise Price
under this subsection (g) (other than a permanent increase) does not change or
adjust the

                                      17
<PAGE>

Exercise Rate otherwise in effect for purposes of subsection (a) and (b) of this
Section 12.

         (h)  When Issuance or Payment May Be Deferred. In any case in which
this Section 12 shall require that an adjustment in the Exercise Rate or
Exercise Price be made effective as of a record date for a specified event, the
Company may elect to defer until the occurrence of such event (i) issuing to the
Holder of any Warrant exercised after such record date the Warrant Shares and
other capital stock of the Company, if any, issuable upon such exercise over and
above the Warrant Shares and other capital stock of the Company, if any,
issuable upon such exercise on the basis of the Exercise Rate prior to such
adjustment, and (ii) paying to such Holder any amount in cash in lieu of a
fractional share pursuant to Section 13 hereof; provided, however, that the
Company shall deliver to the Warrant Agent and shall cause the Warrant Agent, on
behalf of and at the expense of the Company, to deliver to such Holder a due
bill or other appropriate instrument evidencing such Holder's right to receive
such additional Warrant Shares, other capital stock and cash upon the occurrence
of the event requiring such adjustment.

         (i)  Reorganizations. In case of (i) any capital reorganization, other
than in the cases referred to in Section 12(a) and (b) hereof and other than any
capital reorganization that does not result in any reclassification of the
outstanding shares of Common Stock into shares of other stock or other
securities or property, or (ii) the consolidation or merger of the Company with
or into another corporation (other than a merger or consolidation in which the
Company is the continuing corporation and which does not result in any
reclassification of the outstanding shares of Common Stock into shares of other
stock or other securities or property), or (iii) the sale of all or
substantially all of the assets of the Company (collectively such actions being
hereinafter referred to as "Reorganizations"), there shall thereafter be
                            ---------------
deliverable upon exercise of any Warrant in accordance with the terms hereof (in
lieu of the number of shares of Common Stock theretofore deliverable) the number
of shares of stock or other securities or property to which a holder of the
number of shares of Common Stock that would otherwise have been deliverable upon
the exercise of such Warrant would have been entitled upon such Reorganization
if the Exercisability Date had occurred and such Warrant had been exercised in
full immediately prior to such Reorganization. In case of any Reorganization,
appropriate adjustment, as determined in good faith by the board of directors of
the Company, whose determination shall be described in a duly adopted resolution
certified by the Company's Secretary or Assistant Secretary, shall be made in
the application of the provisions herein set forth with respect to the rights
and interests of Holders so that the provisions set forth herein shall
thereafter be applicable, as nearly

                                      18
<PAGE>

as possible, in relation to any such shares or other securities or property
thereafter deliverable upon exercise of Warrants.

         The Company shall not effect any such Reorganization unless prior to or
simultaneously with the consummation thereof the successor corporation (if other
than the Company) resulting from such Reorganization or the corporation or other
entity purchasing such assets shall expressly assume, by a supplemental warrant
agreement or other acknowledgment executed and delivered to the Warrant Agent,
the obligation to deliver to the Warrant Agent and to cause the Warrant Agent to
deliver to each such Holder such shares of stock, securities or assets as, in
accordance with the foregoing provisions, such Holder may be entitled to
purchase in accordance with the terms hereof upon the occurrence of the
Exercisability Date, and the due and punctual performance and observance of each
and every covenant, condition, obligation and liability under this Agreement to
be performed and observed by the Company in the manner prescribed herein.

         The foregoing provisions of this Section 12(i) shall apply to
successive Reorganization transactions.

         (j)  Form of Warrants. Irrespective of any adjustments in the number or
kind of shares purchasable upon the exercise of the Warrants, Warrants
theretofore or thereafter issued may continue to express the same price and
number and kind of shares as are stated in the Warrants initially issuable
pursuant to this Agreement.

         (k)  Warrant Agent's Disclaimer. The Warrant Agent has no duty to
determine when an adjustment under this Section 12 should be made, how it should
be made or what it should be. The Warrant Agent has no duty to determine whether
any provisions of a supplemental warrant agreement under subsection (i) of this
Section 12 are correct. The Warrant Agent makes no representation as to the
validity or value of any securities or assets issued upon exercise of Warrants.
The Warrant Agent shall not be responsible for the Company's failure to comply
with this Section 12.

         (l)  Miscellaneous. For purpose of this Section 12 the term "shares of
Common Stock" shall mean (i) shares of the class of stock designated as the
Common Stock, par value $.01 per share, of the Company as of the date of this
Agreement, and (ii) shares of any other class of stock resulting from successive
changes or reclassification of such shares consisting solely of changes in par
value, or from par value to no par value, or from no par value to par value. In
the event that at any time, as a result of an adjustment made pursuant to this
Section 12, the Holders

                                      19
<PAGE>

of Warrants shall become entitled to purchase any securities of the Company
other than, or in addition to, shares of Common Stock, thereafter the number or
amount of such other securities so purchasable upon exercise of each Warrant
shall be subject to adjustment from time to time in a manner and on terms as
nearly equivalent as practicable to the provisions with respect to the Warrant
Shares contained in subsections (a) through (l) of this Section 12, inclusive,
and the provisions of Sections 7, 8, 10 and 13 with respect to the Warrant
Shares or the Common Stock shall apply on like terms to any such other
securities.

         Section 13.  Fractional Interests. The Company shall not be required to
                      --------------------
issue fractional Warrant Shares on the exercise of Warrants. If more than one
Warrant shall be presented for exercise in full at the same time by the same
Holder, the number of full Warrant Shares which shall be issuable upon the
exercise thereof shall be computed on the basis of the aggregate number of
Warrant Shares purchasable on exercise of the Warrants so presented. If any
fraction of a Warrant Share would, except for the provisions of this Section 13,
be issuable on the exercise of any Warrants (or specified portion thereof), the
Company shall pay an amount in cash equal to the excess of the Current Market
Value of a Warrant Share over the Exercise Price on the day immediately
preceding the date the Warrant is presented for exercise, multiplied by such
fraction.

         Section 14.  Notices to Warrant Holders; Reservation of Dividends. No
                      ----------------------------------------------------
later than April 6, 2001, the Company shall give written notice of the
occurrence or non-occurrence of the Adjustment Event to the Warrant Agent and
shall cause the Warrant Agent, on behalf of and at the expense of the Company,
within 10 days after such notification is received by the Warrant Agent, to mail
by first class mail, postage prepaid, to each Holder a notice of such occurrence
or non-occurrence of the Adjustment Event. Upon any adjustment pursuant to
Section 12 hereof, the Company shall give prompt written notice of such
adjustment to the Warrant Agent and shall cause the Warrant Agent, on behalf of
and at the expense of the Company, within 10 days after notification is received
by the Warrant Agent of such adjustment, to mail by first class mail, postage
prepaid, to each Holder a notice of such adjustment(s) and shall deliver to the
Warrant Agent a certificate of the Chief Financial Officer of the Company,
setting forth in reasonable detail (i) the number of Warrant Shares purchasable
upon the exercise of each Warrant and the Exercise Price of such Warrant after
such adjustment(s), (ii) a brief statement of the facts requiring such
adjustment(s) and (iii) the computation by which such adjustment(s) was made.
Where appropriate, such notice may be given in advance and included as a part of
the notice required under the other provisions of this Section 14.

                                      20
<PAGE>

         In case the Exercisability Date has occurred and:

         (a)  the Company shall authorize the issuance to all holders of shares
of Common Stock of rights, options or warrants to subscribe for or purchase
shares of Common Stock or of any other subscription rights or warrants; or

         (b)  the Company shall authorize the distribution to all holders of
shares of Common Stock of evidences of its indebtedness or assets or cash; or

         (c)  of any consolidation or merger to which the Company is a party and
for which approval of any stockholders of the Company is required, or of the
conveyance or transfer of the properties and assets of the Company substantially
as an entirety, or of any reclassification or change of Common Stock issuable
upon exercise of the Warrants (other than a change in par value, or from par
value to no par value, or from no par value to par value, or as a result of a
subdivision or combination), or a tender offer or exchange offer for shares of
Common Stock; or

         (d)  of the voluntary or involuntary dissolution, liquidation or
winding up of the Company; or

         (e)  the Company proposes to take any action that would require an
adjustment to the Exercise Rate pursuant to Section 12 hereof;

then the Company shall give prompt written notice to the Warrant Agent and shall
cause the Warrant Agent, on behalf of and at the expense of the Company to give
to each of the registered holders of the Warrant Certificates at his, her or its
address appearing on the Warrant Register, at least 30 days (or 20 days in any
case specified in clauses (a) or (b) above) prior to the applicable record date
hereinafter specified, or the date of the event in the case of events for which
there is no record date, by first-class mail, postage prepaid, a written notice
stating (i) the date as of which the holders of record of shares of Common Stock
to be entitled to receive any such rights, options, warrants or distribution are
to be determined, or (ii) the initial expiration date set forth in any tender
offer or exchange offer for shares of Common Stock, or (iii) the date on which
any such consolidation, merger, conveyance, transfer, dissolution, liquidation
or winding up is expected to become effective or consummated, and the date as of
which it is expected that holders of record of shares of Common Stock shall be
entitled to exchange such shares for securities or other property, if any,
deliverable upon such reclassification, consolidation, merger, conveyance,
transfer, dissolution, liquidation or winding up. The failure by the Company or
the Warrant Agent to give such notice or any defect therein shall not

                                      21
<PAGE>

affect the legality or validity of any distribution, right, option, warrant,
consolidation, merger, conveyance, transfer, dissolution, liquidation or winding
up, or the vote upon any action.

         The Company shall give prompt written notice to the Warrant Agent and
shall cause the Warrant Agent, on behalf of and at the expense of the Company to
give to each Holder written notice of any determination to make a distribution
or dividend to the holders of its Common Stock of any assets (including cash
(other than any Ordinary Cash Distribution)), debt securities, preferred stock,
or any rights or warrants to purchase debt securities, preferred stock, assets
or other securities (other than Common Stock, or rights, options, or warrants to
purchase Common Stock) of the Company, which notice shall state the nature and
amount of such planned dividend or distribution and the record date therefor,
and shall be given by the Company at least 20 days prior to such record date
therefor.

         At any time prior to the date that is 30 Business Days after the
Exercisability Date, with respect to any distribution or dividend made by the
Company to all of the holders of its Common Stock for which notice to the
Holders of the Warrants under this Section 14 would be required had such
dividend or distribution occurred after the Exercisability Date and except for
such distributions or dividends as are provided for in Section 12 hereof, the
Company shall hold in reserve the amount of any such dividend or distribution
that would have been payable to the Holders in respect of their Warrant Shares
had the Holders exercised their Warrants immediately prior to such dividend or
distribution. The Company shall release to each Holder of Warrants his, her or
its pro rata share of such reserved dividends or distributions upon the exercise
of such Holder's Warrants pursuant to Section 7 hereof. Any notice delivered to
the Holders by the Company pursuant to this Section 14 shall state the nature
and amount of such dividend or distribution that shall be held in reserve.

         Nothing contained in this Agreement or in any Warrant Certificate shall
be construed as conferring upon the Holders the right to vote or to consent or
to receive notice as stockholders in respect of the meetings of stockholders or
the election of directors of the Company or any other matter, or any rights
whatsoever as stockholders of the Company.

         Section 15.  Notices to the Company and Warrant Agent. Any notice or
                      ----------------------------------------
demand authorized by this Agreement to be given or made by the Warrant Agent or
by any Holder to or on the Company shall be sufficiently given or made when
received at the office of the Company expressly designated by the Company as its

                                      22
<PAGE>

office for purposes of this Agreement (until the Warrant Agent is otherwise
notified in accordance with this Section 15 by the Company), as follows:

                  Endo Pharmaceuticals Holdings Inc.
                  c/o Kelso & Company
                  320 Park Avenue
                  24th Floor
                  New York, New York 10022
                  Attention: Managing Director

                  with a copy to General Counsel

                  with a copy to:

                  Skadden, Arps, Slate, Meagher & Flom LLP
                  Four Times Square
                  New York, New York 10036-6522
                  Attention: Eileen T. Nugent, Esq.

         Any notice pursuant to this Agreement to be given by the Company or by
any Holder(s) to the Warrant Agent shall be sufficiently given when received by
the Warrant Agent at the address appearing below (until the Company is otherwise
notified in accordance with this Section by the Warrant Agent).

                  United States Trust Company of New York
                  114 West 47th Street, 25th Floor
                  New York, New York 10036
                  Attention: Corporate Trust Division

         Section 16.  Supplements and Amendments; Actions. The Company and the
                      -----------------------------------
Warrant Agent may from time to time supplement or amend this Agreement without
the approval of any holders of Warrants in order to cure any ambiguity or to
correct or supplement any provision contained herein which may be defective or
inconsistent with any other provision herein, or to make any other provisions in
regard to matters or questions arising hereunder which the Company and the
Warrant Agent may deem necessary or desirable and which shall not in any way
adversely affect the rights of any holder of Warrants hereunder. Any amendment
or supplement to this Agreement that has a material adverse effect on the rights
of holders hereunder shall require the written consent of registered holders of
a majority of the then outstanding Warrants, which consent shall then be
effective against all the

                                      23
<PAGE>

Holders of Warrants hereunder. The consent of each holder of a Warrant affected
shall be required for any amendment pursuant to which the Exercise Price would
be increased or the number of Warrant Shares purchasable upon exercise of
Warrants would be decreased (not including adjustments contemplated hereunder).
The Warrant Agent shall be entitled to receive and shall be fully protected in
relying upon an officers'certificate and opinion of counsel as conclusive
evidence that any such amendment or supplement is authorized or permitted
hereunder, that it is not inconsistent herewith, and that it will be valid and
binding upon the Company in accordance with its terms.

         Any actions seeking enforcement of the rights of Holders hereunder
(including paragraph 3 of Section 7 hereof) may be brought either by the Warrant
Agent or the Holders of more than 50% of the Warrants issued hereunder and then
outstanding.

         Section 17.  Concerning the Warrant Agent. The Warrant Agent undertakes
                      ----------------------------
the duties and obligations imposed by this Agreement upon the following terms
and conditions, by all of which the Company and the Holders, by their acceptance
of Warrants, shall be bound:

         (a)  The statements contained herein and in the Warrant Certificate
shall be taken as statements of the Company, and the Warrant Agent assumes no
responsibility for the correctness of any of the same except such as describe
the Warrant Agent or any action taken by it. The Warrant Agent assumes no
responsibility with respect to the distribution of the Warrants except as herein
otherwise provided.

         (b)  The Warrant Agent shall not be responsible for any failure of the
Company to comply with the covenants contained in this Agreement or in the
Warrants to be complied with by the Company.

         (c)  The Warrant Agent may execute and exercise any of the rights or
powers hereby vested in it or perform any duty hereunder either itself (through
its employees) or by or through its attorneys or agents (which shall not include
its employees) and shall not be responsible for the misconduct of any agent
appointed with due care.

         (d)  The Warrant Agent may consult at any time with legal counsel
satisfactory to it (who may be counsel for the Company), and the Warrant Agent
shall incur no liability or responsibility to the Company or to any Holder in
respect

                                      24
<PAGE>

of any action taken, suffered or omitted by it hereunder in good faith and in
accordance with the opinion or the advice of such counsel.

         (e)  Whenever in the performance of its duties under this Agreement the
Warrant Agent shall deem it necessary or desirable that any fact or matter be
proved or established by the Company prior to taking or suffering any action
hereunder, such fact or matter (unless such evidence in respect thereof be
herein specifically prescribed) may be deemed to be conclusively proved and
established by a certificate signed by the Chairman of the Board, the President,
Chief Financial Officer, one of the Vice Presidents, the Treasurer or the
Secretary of the Company and delivered to the Warrant Agent; and such
certificate shall be full authorization to the Warrant Agent for any action
taken or suffered in good faith by it under the provisions of this Agreement in
reliance upon such certificate.

         (f)  The Company agrees to pay the Warrant Agent reasonable
compensation for all services rendered by the Warrant Agent in the performance
of its duties under this Agreement, to reimburse the Warrant Agent for all
expenses, taxes and governmental charges and other charges of any kind and
nature incurred by the Warrant Agent (including reasonable fees and expenses of
the Warrant Agent's counsel and agents) in the performance of its duties under
this Agreement, and to indemnify the Warrant Agent and save it harmless against
any and all liabilities, including judgments, costs and counsel fees, for
anything done or omitted by the Warrant Agent in the performance of its duties
under this Agreement, except as a result of the Warrant Agent's negligence or
bad faith.

         (g)  The Warrant Agent shall be under no obligation to institute any
action, suit or legal proceeding or to take any other action likely to involve
expense unless the Company or one or more Holders shall furnish the Warrant
Agent with reasonable security and indemnity satisfactory to the Warrant Agent
for any costs and expenses which may be incurred, but this provision shall not
affect the power of the Warrant Agent to take such action as the Warrant Agent
may consider proper, whether with or without any such security or indemnity. All
rights of action under this Agreement or under any of the Warrants may be
enforced by the Warrant Agent without the possession of any of the Warrants or
the production thereof at any trial or other proceeding relative thereto, and
any such action, suit or proceeding instituted by the Warrant Agent shall be
brought in its name as Warrant Agent, and any recovery of judgment shall be for
the ratable benefit of the Holders, as their respective rights or interests may
appear.

                                      25
<PAGE>

         (h)  The Warrant Agent and any stockholder, director, officer or
employee of the Warrant Agent may buy, sell or deal in any of the Warrants or
other securities of the Company or become pecuniarily interested in any
transactions in which the Company may be interested, or contract with or lend
money to the Company or otherwise act as fully and freely as though it were not
Warrant Agent under this Agreement or such director, officer or employee.
Nothing herein shall preclude the Warrant Agent from acting in any other
capacity for the Company or for any other legal entity including, without
limitation, acting as Transfer Agent or as a lender to the Company or an
Affiliate thereof.

         (i)  The Warrant Agent shall act hereunder solely as agent, and its
duties shall be determined solely by the provisions hereof. The Warrant Agent
shall not be liable for anything which it may do or refrain from doing in
connection with this Agreement except for its own negligence or bad faith.

         (j)  The Warrant Agent will not incur any liability or responsibility
to the Company or to any Holder for any action taken in reliance on any notice,
resolution, waiver, consent, order, certificate, or other paper, document or
instrument reasonably believed by it to be genuine and to have been signed, sent
or presented by the proper party or parties.

         (k)  The Warrant Agent shall not be under any responsibility in respect
of the validity of this Agreement or the execution and delivery hereof (except
the due execution hereof by the Warrant Agent) or in respect of the validity or
execution of any Warrant (except its countersignature thereof); nor shall the
Warrant Agent by any act hereunder be deemed to make any representation or
warranty as to the authorization or reservation of any Warrant Shares (or other
stock) to be issued pursuant to this Agreement or any Warrant, or as to whether
any Warrant Shares (or other stock) will, when issued, be validly issued, fully
paid and nonassessable, or as to the Exercise Price or the number or amount of
Warrant Shares or other securities or other property issuable upon exercise of
any Warrant.

         (l)  The Warrant Agent is hereby authorized and directed to accept
instructions with respect to the performance of its duties hereunder from the
Chairman of the Board, the President, any Vice President or the Secretary of the
Company, and to apply to such officers for advice or instructions in connection
with its duties, and shall not be liable for any action taken or suffered to be
taken by it in good faith and without negligence in accordance with instructions
of any such officer or officers.

                                      26
<PAGE>

         Section 18.  Change of Warrant Agent. The Warrant Agent may resign at
                      -----------------------
any time and be discharged from its duties under this Agreement by giving to the
Company 30-days' notice in writing. The Warrant Agent may be removed by like
notice to the Warrant Agent from the Company. If the Warrant Agent shall resign
or be removed or shall otherwise become incapable of acting, the Company shall
appoint a successor to the Warrant Agent. If the Company shall fail to make such
appointment within a period of 30 days after such removal or after it has been
notified in writing of such resignation or incapacity by the resigning or
incapacitated Warrant Agent or by any Holder (who shall with such notice submit
his, her or its Warrant for inspection by the Company), then any Holder may
apply to any court of competent jurisdiction for the appointment of a successor
to the Warrant Agent. Pending appointment of a successor warrant agent, either
by the Company or by such court, the duties of the Warrant Agent shall be
carried out by the Company. Any successor warrant agent, whether appointed by
the Company or such a court, shall be a bank or trust company in good standing,
incorporated under the laws of the United States of America or any State thereof
or the District of Columbia and having at the time of its appointment as warrant
agent a combined capital and surplus of at least $10,000,000. After appointment,
the successor warrant agent shall be vested with the same powers, rights, duties
and responsibilities as if it had been originally named as Warrant Agent without
further act or deed; but the former Warrant Agent shall deliver and transfer to
the successor warrant agent any property at the time held by it hereunder, and
execute and deliver any further assurance, conveyance, act or deed necessary for
such purpose. Failure to file any notice provided for in this Section 18,
however, or any defect therein, shall not affect the legality or validity of the
resignation or removal of the Warrant Agent or the appointment of the successor
warrant agent, as the case may be. In the event of such resignation or removal,
the Company or the successor warrant agent shall mail by first class mail,
postage prepaid, to each Holder, written notice of such removal or resignation
and the name and address of such successor warrant agent.

         Section 19.  Successors. All the covenants and provisions of this
                      ----------
Agreement by or for the benefit of the Company, the Warrant Agent or any holder
of Warrants shall bind and inure to the benefit of their respective successors
and assigns hereunder.

         Section 20.  Termination. This Agreement shall terminate at 5:00 p.m.,
                      -----------
New York City time, on the Expiration Date. Notwithstanding the foregoing, this
Agreement will terminate on any earlier date if all Warrants have been exercised
pursuant to this Agreement.

                                      27
<PAGE>

         Section 21.  GOVERNING LAW. THIS AGREEMENT AND EACH WARRANT CERTIFICATE
                      -------------
ISSUED HEREUNDER SHALL BE DEEMED TO BE A CONTRACT MADE UNDER THE LAWS OF THE
STATE OF NEW YORK AND SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE
LAWS OF SAID STATE, WITHOUT REGARD TO THE CONFLICT OF LAW RULES THEREOF.

         Section 22.  Benefits of This Agreement. Nothing in this Agreement
                      --------------------------
shall be construed to give to any person or corporation other than the Company,
the Warrant Agent and the registered Holders of the Warrant Certificates any
legal or equitable right, remedy or claim under this Agreement; but this
Agreement shall be for the sole and exclusive benefit of the Company, the
Warrant Agent and the registered Holders of the Warrant Certificates.

         Section 23.  Counterparts. This Agreement may be executed in any number
                      ------------
of counterparts and each of such counterparts shall for all purposes be deemed
to be an original, and all such counterparts shall together constitute but one
and the same instrument.

         Section 24.  Headings. The headings in this Agreement are for
                      --------
convenience of reference only and shall not limit or otherwise affect the
meaning hereof.

                                      28
<PAGE>

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed, as of the day and year first above written.

                               ENDO PHARMACEUTICALS HOLDINGS INC.

                               By: /s/ JEFFREY R. BLACK
                                   ---------------------------------------------
                               Name:    Jeffrey R. Black
                               Title:   Chief Financial Officer

                               UNITED STATES TRUST COMPANY OF NEW YORK,
                               as Warrant Agent

                               By: /s/ SIROJNI DINDIAL
                                   ---------------------------------------------
                               Name:    Sirojni Dindial
                               Title:   Assistant Vice President
<PAGE>

                                                                       EXHIBIT A

                         [Form of Warrant Certificate]
                                    [Face]

         THIS SECURITY IS A GLOBAL CERTIFICATE AND IS REGISTERED IN THE NAME OF
A DEPOSITORY OR A NOMINEE OF A DEPOSITORY OR A SUCCESSOR DEPOSITORY. THIS
SECURITY IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON
OTHER THAN THE DEPOSITORY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES
DESCRIBED IN THE WARRANT AGREEMENT, DATED AS OF JULY 17, 2000, BY AND BETWEEN
THE COMPANY AND THE WARRANT AGENT (THE "WARRANT AGREEMENT"), AND NO TRANSFER OF
THIS SECURITY (OTHER THAN A TRANSFER OF THIS SECURITY AS A WHOLE BY THE
DEPOSITORY TO A NOMINEE OF THE DEPOSITORY OR BY A NOMINEE OF THE DEPOSITORY TO
THE DEPOSITORY OR ANOTHER NOMINEE OF THE DEPOSITORY) MAY BE REGISTERED EXCEPT IN
THE LIMITED CIRCUMSTANCES DESCRIBED IN THE WARRANT AGREEMENT. UNLESS THIS
CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST
COMPANY (A NEW YORK CORPORATION) ("DTC") TO THE ISSUER OR ITS AGENT FOR
REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS
REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN
AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR SUCH
OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY
TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON
IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST
HEREIN

                                      A-1
<PAGE>

                EXERCISABLE ON OR AFTER THE EXERCISABILITY DATE
                     AND ON OR BEFORE THE EXPIRATION DATE

No. _______                                      Class A Transferable Warrants

                   Class A Transferable Warrant Certificate

                      ENDO PHARMACEUTICALS HOLDINGS INC.

         This Warrant Certificate certifies that, or registered assigns, is the
registered holder of Class A Transferable Warrants expiring on or before the
Expiration Date (the "Warrants") to purchase shares of Common Stock, par value
$.01 per share (the "Common Stock"), of Endo Pharmaceuticals Holdings Inc., a
Delaware corporation (the "Company"). Each Warrant entitles the holder upon
exercise to receive from the Company on or after the Exercisability Date and on
or before 5:00 p.m. New York City Time on the six-month anniversary of the
Exercisability Date (the "Expiration Date") a number of fully paid and
nonassessable shares of Common Stock (each such share, a "Warrant Share") as
determined in the following paragraph at the initial exercise price (the
"Exercise Price") equal to $0.01 per share payable upon surrender of this
Warrant Certificate and payment of the Exercise Price in the manner set forth in
the Warrant Agreement, subject only to the conditions set forth herein and in
the Warrant Agreement referred to on the reverse hereof.

         If the Exercisability Date is on or prior to March 31, 2002, the Holder
shall then be entitled to receive from the Company (on exercise of such Warrants
and payment of the Exercise Price then in effect for such Warrant Shares)
(together, if applicable, with cash payable as provided in Section 13 hereof and
any dividends or distributions payable as provided in Section 14 hereof) (a)
1.153846 Warrant Shares in the event the Adjustment Event (as defined in that
certain Agreement and Plan of Merger, dated as of November 26, 1999, by and
among the Company, Endo Inc., a Delaware corporation and wholly owned subsidiary
of the Company, and Algos Pharmaceutical Corporation, a Delaware corporation)
has not occurred prior to the Exercisability Date or (b) 1.000000 Warrant Shares
in the event the Adjustment Event has occurred prior to the Exercisability Date.
If the Exercisability Date is after March 31, 2002 and on or prior to September
30, 2002, the Holder shall then be entitled to receive from the Company (on
exercise of such Warrants and payment of the Exercise Price then in effect for
such Warrant Shares) (together, if applicable, with cash payable as provided in
Section 13 hereof and any dividends or distributions payable as provided in
Section 14 hereof) (a) 0.633803 Warrant Shares in the event the Adjustment Event
has not occurred prior to the Exercisability Date or (b) 0.545455 Warrant Shares
in the event the Adjustment Event has occurred prior to the Exercisability Date.
If the Exercisability Date is after September 30, 2002 and on or prior to March
31, 2003, the Holders shall then be entitled to receive from the Company (on

                                      A-2
<PAGE>

exercise of such Warrants and payment of the Exercise Price then in effect for
such Warrant Shares) (together, if applicable, with cash payable as provided in
Section 13 hereof and any dividends or distributions payable as provided in
Section 14 hereof) (a) 0.263158 Warrant Shares in the event the Adjustment Event
has not occurred prior to the Exercisability Date or (b) 0.225352 Warrant Shares
in the event the Adjustment Event has occurred prior to the Exercisability Date.

     The Exercise Price and number of Warrant Shares issuable upon exercise of
the Warrants are subject to adjustment upon the occurrence of certain events as
set forth in the Warrant Agreement.

     No Warrant may be exercised before the Exercisability Date or after
5:00 p.m., New York City Time, on the Expiration Date and to the extent not
exercised by such time such Warrants shall become void.

     This Warrant Certificate shall not be valid unless countersigned by the
Warrant Agent, as such term is used in the Warrant Agreement.

     THIS WARRANT CERTIFICATE SHALL BE GOVERNED BY, AND CONSTRUED IN
ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

                                      A-3
<PAGE>

     IN WITNESS WHEREOF, Endo Pharmaceuticals Holdings Inc. has caused this
Warrant Certificate to be signed by an officer and by its Secretary, each by a
facsimile of his or her signature, and has caused a facsimile of its corporate
seal to be affixed hereunto or imprinted hereon.

Dated:
                                        ENDO PHARMACEUTICALS HOLDINGS INC.

                                        By: _________________________________
                                            Name:
                                            Title:

                                        By: _________________________________
                                            Name:
                                            Title:

Countersigned:

UNITED STATES TRUST COMPANY
OF NEW YORK,
  as Warrant Agent

By: _________________________________
    Name:
    Title:

                                      A-4
<PAGE>

                         [Form of Warrant Certificate]
                                   [Reverse]

     The Warrants evidenced by this Warrant Certificate are part of a duly
authorized issue of Warrants expiring on the "Expiration Date," entitling the
holder on exercise to receive shares of Common Stock, par value $.01 per share,
of the Company (the "Common Stock"), and are issued or to be issued pursuant to
a Warrant Agreement dated as of July 17, 2000 (the "Warrant Agreement"), duly
executed and delivered by the Company to United States Trust Company of New
York, as warrant agent (the "Warrant Agent"), which Warrant Agreement is hereby
incorporated by reference in and made a part of this instrument and is hereby
referred to for a description of the rights, limitation of rights, obligations,
duties and immunities thereunder of the Warrant Agent, the Company and the
holders (the words "holders" or "holder" meaning the registered holders or
registered holder) of the Warrants. A copy of the Warrant Agreement may be
obtained by the holder hereof upon written request to the Company.

     Warrants may be exercised at any time on or after the "Exercisability
Date" and on or before the "Expiration Date." The holder of Warrants evidenced
by this Warrant Certificate may exercise them by surrendering this Warrant
Certificate, with the form of election to purchase set forth hereon properly
completed and executed, together with payment in the manner provided for in the
Warrant Agreement at the office of the Warrant Agent. In the event that upon any
exercise of Warrants evidenced hereby, the number of Warrants exercised shall be
less than the total number of Warrants evidenced hereby, there shall be issued
to the holder hereof or his, her or its assignee a new Warrant Certificate
evidencing the number of Warrants not exercised.

     The Warrant Agreement provides that upon the occurrence of certain events
the number of Warrants set forth on the face hereof and the Exercise Price may,
subject to certain conditions, be adjusted. No fractions of a share of Common
Stock will be issued upon the exercise of any Warrant, but the Company will pay
the cash value thereof determined as provided in the Warrant Agreement.

     Warrant Certificates, when surrendered at the office of the Warrant
Agent by the registered holder thereof in person or by legal representative or
attorney duly authorized in writing, may be exchanged, in the manner and subject
to the limitations provided in the Warrant Agreement, but without payment of any
service charge, for another Warrant Certificate or Warrant Certificates of like
tenor evidencing in the aggregate a like number of Warrants.

                                      A-5
<PAGE>

     Upon due presentation for registration of transfer of this Warrant
Certificate at the office of the Warrant Agent a new Warrant Certificate or
Warrant Certificates of like tenor and evidencing in the aggregate a like number
of Warrants shall be issued to the transferee(s) in exchange for this Warrant
Certificate, subject to the limitations provided in the Warrant Agreement,
without charge except for any tax or other governmental charge imposed in
connection therewith.

     The Company and the Warrant Agent may deem and treat the registered
holder(s) thereof as the absolute owner(s) of this Warrant Certificate
(notwithstanding any notation of ownership or other writing hereon made by
anyone), for the purpose of any exercise hereof, of any distribution to the
holder(s) hereof, and for all other purposes, and neither the Company nor the
Warrant Agent shall be affected by any notice to the contrary. Neither the
Warrants nor this Warrant Certificate entitles any holder hereof to any rights
of a stockholder of the Company.

                                      A-6
<PAGE>

                        [Form of Election to Purchase]

                   (To Be Executed upon Exercise of Warrant)

     The undersigned hereby irrevocably elects to exercise the right,
represented by this Warrant Certificate, to receive shares of Common Stock and
herewith tenders payment for such shares to the order of Endo Pharmaceuticals
Holdings Inc. in the amount of $_______ payable in (select one or more: (i) cash
and/or (ii) pursuant to a Cashless Exercise) in accordance with the terms hereof
and of the Warrant Agreement. The undersigned requests that a certificate for
such shares be registered in the name of _____________________, whose address is
_____ ______________________________ and that such shares be delivered to

______________________whose address is ______________________________. If said
number of shares is less than all of the shares of Common Stock purchasable
hereunder, the undersigned requests that a new Warrant Certificate representing
the remaining balance of such shares be registered in the name of
_____________________, whose address is _____________________________, and that
such Warrant Certificate be delivered to__________________________, whose
address is ________________________________.

                                                     Signature:
Date:

                                                     Signature Guaranteed:

                                      A-7
<PAGE>

                SCHEDULE OF EXCHANGES OF CERTIFICATED WARRANTS

                The following exchanges of a part of this Global Warrant for
certificated Warrants have been made:

                                                                   Number of
                                                                  Warrants of

               Amount of          Amount of        this Global
              decrease in        increase in         Warrant       Signature of
               Number of          Number of         following       authorized
Date of    Warrants of this   Warrants of this    such decrease     officer of
Exchange    Global Warrant     Global Warrant     (or increase)    Warrant Agent
--------    --------------     --------------       ------------- -- -----------

                                      A-8
<PAGE>

                                                                       EXHIBIT B

                   CERTIFICATE TO BE DELIVERED UPON EXCHANGE
                        OR REGISTRATION OF TRANSFER OF
                         CLASS A TRANSFERABLE WARRANTS

Re:      Class A Transferable Warrants to Purchase Common Stock (the "Warrants")
         of Endo Pharmaceuticals Holdings Inc.

         This Certificate relates to Warrants held in* book-entry or *
certificated form by (the "Transferor").

The Transferor:*

[_]    has requested the Warrant Agent by written order to deliver in exchange
       for its beneficial interest in the Global Warrant held by the depository
       a Warrant or Warrants in definitive, registered form equal to its
       beneficial interest in Warrants represented by such Global Warrant (or
       the portion thereof indicated above); or

[_]    has requested the Warrant Agent by written order to deliver in exchange
       or register the transfer of a Warrant or Warrants.

                                            ------------------------------------
                                            [INSERT NAME OF TRANSFEROR]

                                            By: ________________________________

Date: ______________________________
*Check applicable box.

                                      B-1
<PAGE>

<TABLE>
<CAPTION>
                            INDEX OF DEFINED TERMS
<S>                                                                         <C>

Affiliate........................................................            17
Agreement........................................................             1
Algos............................................................             1
Business Day.....................................................             9
Cashless Exercise................................................            10
Class A Transferable Warrants....................................             1
Class A Warrant Certificates................ ....................             2
Class B Non-Transferable Warrants................................             1
closing bid price................................................            16
Common Stock.....................................................   1, A-2, A-5
Company..........................................................        1, A-2
Current Market Value.............................................            16
Definitive Warrants..............................................             2
DTC..............................................................           A-1
Exchange Act.....................................................            16
Exercisability Date..............................................        9, A-5
Exercise Price...................................................       10, A-2
Exercise Rate....................................................            13
Expiration Date..................................................   8, A-2, A-5
FDA..............................................................             9
Fully Diluted Shares.............................................            15
Global Warrants..................................................             2
Holders..........................................................             3
Independent Financial Expert.....................................            16
Legal Holiday....................................................             9
Merger Agreement.................................................             1
Ordinary Cash Distribution.......................................            17
Reorganizations..................................................            18
shares of Common Stock...     .......  ..........................            20
Sub..............................................................             1
Time of Determination................. ..........................            14
Transfer Agent...................................................            12
Transferor.......................................................           B-1
Ultimate Expiration Date.....................  ..................             8
Warrant..........................................................             1
Warrant Agent....................................................        1, A-5
Warrant Agreement................................................      A-1, A-5
Warrant Register.................................................             3
</TABLE>

                                      ii
<PAGE>

<TABLE>                                                              <C>
<S>
Warrant Share....................................................         A-2
Warrant Shares...................................................           1
Warrants ........................................................    A-2, B-1
</TABLE>

                                      iii<PAGE>

                                                                    EXHIBIT 10.5

                             TAX SHARING AGREEMENT
                             ---------------------

          This TAX SHARING AGREEMENT (the "Agreement") by and among Endo
                                           ---------
Pharmaceuticals Holdings Inc., a Delaware corporation ("Endo"), Endo Inc., a
                                                        ----
Delaware corporation and wholly owned subsidiary of Endo, and Endo Pharma LLC, a
Delaware limited liability company ("Endo LLC"), is effective as of this 17th
                                     --------
day of July, 2000.

          WHEREAS the members of Endo LLC have agreed to exchange the shares of
common stock, par value $.01 per share, of Endo ("Endo Common Stock") currently
                                                  -----------------
beneficially owned by them for membership interests of Endo LLC;

          WHEREAS under the Parent Plan certain officers and employees of Endo
have been granted stock options exercisable against Endo to purchase newly
issued shares of Endo Common Stock in certain circumstances;

          WHEREAS Endo and Endo Inc. entered into an Agreement and Plan of
Merger with Algos Pharmaceutical Corporation, a Delaware corporation, on
November 26, 1999 (as may be amended and restated from time to time, the "Merger
                                                                          ------
Agreement");
---------

          WHEREAS in connection with the Merger, employee stock options granted
or to be granted under the Parent Plan will be amended as provided in Section
5.9 of the Merger Agreement in order to provide that such options will be
exercisable solely into shares of Parent Common Stock that are beneficially
owned by certain holders of Parent Common Stock immediately following the Parent
Recapitalization and prior to the Effective Time (such amended options, the
"Endo LLC Options");
-----------------

          WHEREAS the shares of Endo Common Stock to be delivered upon exercise
of the Endo LLC Options will be provided entirely by Endo LLC and not directly
or indirectly by Endo or any other Endo stockholder; and

          WHEREAS under the Internal Revenue Code of 1986, as amended (the
"Code") and the Treasury Regulations, rulings and other interpretations
 ----
thereunder, deductible compensation expense resulting from the exercise of a
Endo LLC
<PAGE>

Option by an Endo officer or employee is treated for income tax purposes as a
deduction of Endo;

          NOW, THEREFORE, in consideration of the premises, representations,
warranties and agreements herein contained, the parties agree as follows:

                                   ARTICLE I

                                   PAYMENTS

     Section 1.1    Payments to Endo LLC.
                    --------------------

          (a) Upon the occurrence of a Liquidity Event, Endo (or any successor
entity) shall pay to Endo LLC or its designees by wire transfer in immediately
available funds in U.S. dollars the Tax Benefit Amount to the extent such Tax
Benefit Amount has not previously resulted in a payment under this Section 1.1.

          (b) For purposes of this Agreement, "Liquidity Event" shall mean any
                                               ---------------
transaction or series of transactions resulting in (A) a sale of greater than
20% on a fully diluted basis of the common equity of Endo through (i) a primary
offering by Endo, (ii) a secondary sale of Endo Common Stock by Endo LLC or
other holders of Endo Common Stock pursuant to a registration rights agreement
or (iii) a combination of primary and secondary offerings described in clauses
(i) and (ii) of this subsection, (B) a Change of Control or (C) a sale of all or
substantially all of the assets of Endo.

          (c) For purposes of this Agreement, "Change of Control" shall mean (i)
                                               -----------------
any merger, consolidation or other business combination that requires the
approval of holder of Endo Common Stock, (ii) any transaction or series of
transactions resulting in an acquisition by any Person (or Persons acting in
concert) unrelated to Endo LLC or its Affiliates of greater than 50% of the
equity of Endo measured by vote or value on a fully diluted basis or (iii) the
consummation by Endo of a plan of complete liquidation or a dissolution of Endo.
<PAGE>

          (d) For purposes of this Agreement, "Tax Benefit Amount" means the
                                               ------------------
cumulative excess (if any) of (A) the Taxes that would have been payable by Endo
and its Subsidiaries for all taxable periods or portions thereof after the
Effective Date if none of the Endo LLC Options had been exercised over (B) the
actual Taxes payable by Endo and its Subsidiaries for such periods. For the
avoidance of doubt and for purposes of this Section 1(d), in order to determine
the Tax Benefit Amount for any taxable period of Endo and its Subsidiaries in
which a net operating loss carryforward deduction ("NOL") is utilized, the
                                                    ---
portion of the NOL attributable to deductions resulting from the exercise of
Endo LLC Options shall be treated as utilized last. By way of example, and
solely for the avoidance of doubt, if Endo has a loss for tax purposes in Year 1
of $100, consisting of $65 of deductions attributable to the exercise of Endo
LLC Options and $35 of deductions attributable to interest expense, and in Year
2 Endo has $40 of taxable income prior to application of the NOL, $35 of the $40
NOL applied against Year 2 income will be deemed to be attributable to the
interest expense and $5 of the NOL will be deemed attributable to the exercise
of the Endo LLC Options. Therefore, the Tax Benefit Amount would be the Taxes
that would have been payable by Endo if its NOL in Year 2 had been only $35. The
NOL carryforward to Year 3 of $60 would then be treated as consisting entirely
of deductions resulting from the exercise of the Endo LLC Options.

          (e) The parties hereby agree that no payments shall be made and no
rights to any payment shall accrue to Endo LLC under this Agreement until the
occurrence of a Liquidity Event, if any, and that Endo and its Subsidiaries
shall not credit to an account of Endo LLC or any other Person, set aside any
funds or assets, or otherwise make available to or subject to a claim of Endo
LLC or any other Person any amounts hereunder until such amounts become payable
to Endo LLC pursuant to Section 1.1(a) hereof.

          (f) The parties hereby agree that, notwithstanding anything herein to
the contrary, (i) any payments made pursuant to this Section 1.1 shall be
treated as payments described in Section 302 of the Code and shall take no
position inconsistent with this treatment for any tax purpose and (ii) no amount
shall be payable hereunder, and Endo LLC shall not be entitled to any payment
hereunder, to the extent any such payment is not permitted under Endo's Senior
Credit Facility, unless or until such time as such payment is either permitted
under the Senior Credit Facility or the Senior Credit Facility is terminated.
For purposes hereof, "Senior Credit Facility" shall mean the Credit Agreement
dated as of August 26, 1997, by and between Endo Pharmaceuticals Inc. and The
Chase Manhattan Bank, as
<PAGE>

amended, restated, modified, renewed, refunded, replaced, or refinanced, in
whole or in part, from time to time.

                                  ARTICLE II

                              GENERAL PROVISIONS

     Section 2.1   Survival  This Agreement shall survive until the later of
                   --------
(a) the close of the last taxable period of Endo or any successor to Endo in
which a deduction may be allowable to Endo or its Subsidiaries or their
successors as a result of or attributable to the exercise of an Option or (b)
the payment by Endo of all amounts payable under Section 1.1 hereof.

     Section 2.2   Notices.  All notices and other communications hereunder
                   -------
shall be in writing and shall be deemed given when delivered personally, one day
after being delivered to an overnight courier or when telecopied (with a
confirmatory copy sent by overnight courier) to the parties at the following
addresses (or at such other address for a party as shall be specified by like
notice):

          (a)  if to Endo or Endo Inc., to:

          Endo Pharmaceuticals Holdings Inc.
          223 Wilmington-West Chester Pike
          Chadds Ford, PA 19317
          Attn.:  Carol A. Ammon
          Fax No.:  (610) 558-9683

          (b)  if to Endo LLC or Kelso & Company:

          Kelso & Company
          320 Park Avenue, 24/th/ Floor
          New York, New York 10022
          Attn.:  James J. Connors, II, Esq.
          Fax No.:  (212) 223-2379
<PAGE>

          and with copies to:

          Skadden, Arps, Slate, Meagher & Flom LLP
          Four Times Square
          New York, NY  10036-6522
          Attn.:  Eileen T. Nugent, Esq. and David Rievman, Esq.
          Fax No.: (212) 735-2000

     Section 2.3  Interpretation.  When a reference is made in this Agreement to
                  --------------
a Section, such reference shall be to a Section of this Agreement unless
otherwise indicated. The headings contained in this Agreement are for reference
purposes only and shall not affect in any way the meaning or interpretation of
this Agreement. Whenever the words "include," "includes" or "including" are used
in this Agreement, they shall be deemed to be followed by the words "without
limitation."

     Section 2.4  Counterparts.  This Agreement may be executed in counter
                  ------------
parts, all of which shall be considered one and the same agreement, and shall
become effective when one or more counterparts have been signed by each of the
parties and delivered to the other parties.

     Section 2.5  Entire Agreement; No Third-Party Beneficiaries.  Except for
                  ----------------------------------------------
the Merger Agreement and the Mutual Confidentiality and Non-Disclosure Agreement
between the parties dated October 21, 1998, this Agreement is the entire
agreement and supersedes all prior agreements and understandings, both written
and oral, among the parties with respect to the subject matter hereof. This
Agreement is not intended to confer upon any Person other than the parties
hereto any rights or remedies hereunder.

     Section 2.6  Governing Law.  This Agreement shall be governed by, and
                  -------------
construed in accordance with, the laws of the State of Delaware, regardless of
the laws that might otherwise govern under applicable principles of conflicts of
laws thereof.  EACH OF THE PARTIES HERETO IRREVOCABLY WAIVES ITS RIGHT TO A
TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR
RELATING TO THIS AGREE MENT OR THE ACTIONS OF ENDO, ENDO LLC OR ENDO INC. IN THE
NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCE MENT THEREOF.
<PAGE>

     Section 2.7   Assignment.  Neither this Agreement nor any of the rights,
                   ----------
interests or obligations hereunder shall be assigned by any of the parties
hereto (whether by operation of law or otherwise) without the prior written
consent of the other parties.  Subject to the preceding sentence, this Agreement
will be binding upon, inure to the benefit of and be enforceable by the parties
and their respective successors and assigns.

     Section 2.8   Severability.  If any term or other provision of this
                   ------------
Agreement is invalid, illegal or incapable of being enforced by any rule of law,
or public policy, all other conditions and provisions of this Agreement shall
nevertheless remain in full force and effect so long as the economic and legal
substance of the transactions contemplated hereby are not affected in any manner
materially adverse to any party. Upon such determination that any term or other
provision is invalid, illegal or incapable of being enforced, the parties shall
negotiate in good faith to modify this Agreement so as to effect the original
intent of the parties as closely as possible in a mutually acceptable manner in
order that the transactions contemplated by this Agreement may be consummated as
originally contemplated to the fullest extent possible.

     Section 2.9   Modifications, Supplements and Amendment.  This Agreement may
                   ----------------------------------------
be modified, supplemented or amended from time to time by the parties hereto;
provided that any such modification, supplement or amendment must be approved by
-------- ----
a majority of the members of the Board of Directors of Endo who do not then (by
themselves or through an Affiliate) have a financial interest in Endo LLC or
otherwise have a financial interest in any payments that may be made by Endo or
any successor to Endo hereunder).

     Section 2.10  Definitions.  Terms not otherwise defined herein have the
                   -----------
meaning given such terms in the Merger Agreement.
<PAGE>

          IN WITNESS WHEREOF, the parties hereto have caused this Agreement to
be signed by their respective officers thereunto duly authorized all as of the
date first written above.

                              ENDO PHARMACEUTICALS HOLDINGS INC.

                              By: /s/ Carol A. Ammon
                                 ---------------------------------------------
                                 Name:  Carol A. Ammon
                                 Title: President & Chief Executive Officer

                              ENDO INC.

                              By: /s/ Carol A. Ammon
                                 ---------------------------------------------
                                 Name:  Carol A. Ammon
                                 Title: President & Chief Executive Officer

                              ENDO PHARMA LLC

                              By: /s/ Jeffrey R. Black
                                 ---------------------------------------------
                                 Name:  Jeffrey R. Black
                                 Title: Chief Financial Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00013-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00013-of-00352.parquet"}]]